RxDoctor Payments Data

Kevin Campbell

Family · Decatur, ALNPI 1477933976

Payments from drug & device makers

$858in general payments, 2019–2025

Across 43 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$264
  • Novo Nordisk$161
  • Paratek Pharmaceuticals, Inc.$88
  • AbbVie$75
  • AstraZeneca$55
  • GSK$47
  • plus $170 from 7 others

What the payments were for

  • Food & beverage$858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$858 in reported general payments places this provider in the 60th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$42,925
Medicare patients
173
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$56,103
TrulicityDulaglutide45$50,821
EliquisApixaban42$39,716
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$38,411
MounjaroTirzepatide26$33,514
XareltoRivaroxaban16$24,042
JardianceEmpagliflozin25$23,479
FarxigaDapagliflozin Propanediol28$22,121
TradjentaLinagliptin21$18,575
RybelsusSemaglutide18$16,883
VraylarCariprazine Hcl12$16,882
Xigduo XrDapaglifloz Propaned/Metformin21$14,459
Tresiba Flextouch U-200Insulin Degludec12$9,068
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,768
Esomeprazole Magnesium64$2,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$264$84,33571 claims
Novo NordiskOzempic, Rybelsus$161$72,98775 claims
GSKTrelegy Ellipta$47$38,41157 claims
AstraZenecaFarxiga, Breztri Aerosphere$55$29,88940 claims
AbbVieVraylar, Synthroid$75$18,25328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,415 family providers in Alabama.

Other family in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →